Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 94

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Acute lymphocytic leukaemia+4

Recruiting

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Dasatinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Juvenile idiopathic arthritis

Recruiting

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Abatacept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Colitis ulcerative

Recruiting

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Parkinson's disease

Not yet recruiting

Efficacy and Safety of Carbidopa/Levodopa (CP-012B) in Participants with Parkinson’s Disease with Early Morning OFF Episodes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Carbidopa
  • Sponsor:Contera Pharma A/S

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.